Characteristic comparison of three rat models induced by cigarette smoke or combined with LPS: To establish a suitable model for study of airway mucus hypersecretion in chronic obstructive pulmonary disease

Pulmonary Pharmacology and Therapeutics

Volumn 25, Issue 5, 2012, Pages 349-356

  Nie, Yi Chu ^a   Wu, Hao ^b   Li, Pei Bo ^a   Luo, Yu Long ^a   Zhang, Chen Chen ^a   Shen, Jian Gang ^b   Su, Wei Wei ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b THE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Activator protein 1; Cigarette smoke; Histone deacetylase 2; LPS; MUC5AC; Mucus hypersecretion; Nuclear factor kappa B

Indexed keywords

CIGARETTE SMOKE; HISTONE DEACETYLASE 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOPOLYSACCHARIDE; MITOGEN ACTIVATED PROTEIN KINASE; MUCIN 5AC; MUCIN 5B; TOLL LIKE RECEPTOR 4; TRANSCRIPTION FACTOR AP 1; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRONCHIOLE; BRONCHUS; CELL HYPERPLASIA; CELL INFILTRATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE EXACERBATION; EMPHYSEMA; GENE EXPRESSION; GOBLET CELL; INFLAMMATORY CELL; MALE; MUCUS SECRETION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; RAT; RESPIRATORY TRACT MUCOSA; SIGNAL TRANSDUCTION; TRACHEA MUCOSA; TRANSCRIPTION INITIATION; WESTERN BLOTTING;

ANIMALS; BRONCHI; DISEASE MODELS, ANIMAL; HISTONE DEACETYLASE 2; LIPOPOLYSACCHARIDES; MALE; MUCIN 5AC; MUCUS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, EPIDERMAL GROWTH FACTOR; SMOKE; TOBACCO; TOLL-LIKE RECEPTOR 4; TRANSCRIPTION FACTOR RELA;

EID: 84865988601     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2012.06.004     Document Type: Article

References (30)

1. Jackson A.D. Airway goblet-cell mucus secretion. Trends Pharmacol Sci 2001, 22:39-45.
2. Evans C.M., Koo J.S. Airway mucus: the good, the bad, the sticky. Pharmacol Ther 2009, 121:332-348.
3. Rogers D.F. Airway mucus hypersecretion in asthma: an undervalued pathology?. Curr Opin Pharmacol 2004, 4:241-250.
4. Rogers D.F. Mucus hypersecretion in chronic obstructive pulmonary disease. Novartis Found Symp 2001, 234:65-77. p. 77-83.
5. Chen R., Lim J.H., Jono H., Gu X.X., Kim Y.S., Basbaum C.B., et al. Nontypeable haemophilus influenzae lipoprotein P6 induces MUC5AC mucin transcription via TLR2-TAK1-dependent p38 MAPK-AP1 and IKKbeta-IKappabalpha-NF-kappaB signaling pathways. Biochem Biophys Res Commun 2004, 324:1087-1094.
6. Chen Y.J., Chen P., Wang H.X., Wang T., Chen L., Wang X., et al. Simvastatin attenuates acrolein-induced mucin production in rats: involvement of the Ras/extracellular signal-regulated kinase pathway. Int Immunopharmacol 2010, 10:685-693.
7. Hauber H.P., Daigneault P., Frenkiel S., Lavigne F., Hung H.L., Levitt R.C., et al. Niflumic acid and MSI-2216 reduce TNF-alpha-induced mucin expression in human airway mucosa. J Allergy Clin Immunol 2005, 115:266-271.
8. Kitazaki T., Soda H., Doi S., Nakano H., Nakamura Y., Kohno S. Gefitinib inhibits MUC5AC synthesis in mucin-secreting non-small cell lung cancer cells. Lung Cancer 2005, 50:19-24.
9. Yoshida T., Tuder R.M. Pathobiology of cigarette smoke-induced chronic obstructive pulmonary disease. Physiol Rev 2007, 87:1047-1082.
10. Li L., Bao H., Wu J., Duan X., Liu B., Sun J., et al. Baicalin is anti-inflammatory in cigarette smoke-induced inflammatory models in vivo and in vitro: a possible role for HDAC2 activity. Int Immunopharmacol 2012, 13:15-22.
11. Ito K., Yamamura S., Essilfie-Quaye S., Cosio B., Ito M., Barnes P.J., et al. Histone deacetylase 2-mediated deacetylation of the glucocorticoid receptor enables NF-kappaB suppression. J Exp Med 2006, 203:7-13.
12. Lee S.Y., Kang E.J., Hur G.Y., Jung K.H., Jung H.C., Lee S.Y., et al. The inhibitory effects of rebamipide on cigarette smoke-induced airway mucin production. Respir Med 2006, 100:503-511.
13. Smirnova M.G., Guo L., Birchall J.P., Pearson J.P. LPS up-regulates mucin and cytokine mRNA expression and stimulates mucin and cytokine secretion in goblet cells. Cell Immunol 2003, 221:42-49.
14. Nakamura S., Yanagihara K., Araki N., Yamada K., Morinaga Y., Izumikawa K., et al. High-dose tobramycin inhibits lipopolysaccharide-induced MUC5AC production in human lung epithelial cells. Eur J Pharmacol 2011, 659:67-71.
15. Martin J.G., Tamaoka M. Rat models of asthma and chronic obstructive lung disease. Pulm Pharmacol Ther 2006, 19:377-385.
16. Wright J.L., Churg A. Animal models of cigarette smoke-induced COPD. Chest 2002, 122:301S-306S.
17. Stevenson C.S., Birrel M.A. Moving towards a new generation of animal models for asthma and COPD with improved clinical relevance. Pharmacol Ther 2011, 130:93-105.
18. Brusselle G.G., Bracke K.R., Maes T., D'hulst A.I., Moerloose K.B., Joos G.F., et al. Murine models of COPD. Pulm Pharmacol Ther 2006, 19:155-165.
19. Zhang G., Ghosh S. Molecular mechanisms of NF-kappaB activation induced by bacterial lipopolysaccharide through Toll-like receptors. J Endotoxin Res 2000, 6:453-457.
20. Chen L., Wang T., Zhang J.Y., Zhang S.F., Liu D.S., Xu D., et al. Toll-like receptor 4 relates to lipopolysaccharide-induced mucus hypersecretion in rat airway. Arch Med Res 2009, 40:10-17.
21. Zheng H., Liu Y., Huang T., Fang Z., Li G., He S. Development and characterization of a rat model of chronic obstructive pulmonary disease (COPD) induced by sidestream cigarette smoke. Toxicol Lett 2009, 189:225-234.
22. Lixuan Z., Jingcheng D., Wenqin Y., Jianhua H., Baojun L., Xiaotao F. Baicalin attenuates inflammation by inhibiting NF-kappaB activation in cigarette smoke induced inflammatory models. Pulm Pharmacol Ther 2010, 23:411-419.
23. Marwick J.A., Kirkham P.A., Stevenson C.S., Danahay H., Giddings J., Butler K., et al. Cigarette smoke alters chromatin remodeling and induces proinflammatory genes in rat lungs. Am J Respir Cell Mol Biol 2004, 31:633-642.
24. Galasinski S.C., Resing K.A., Goodrich J.A., Ahn N.G. Phosphatase inhibition leads to histone deacetylases 1 and 2 phosphorylation and disruption of corepressor interactions. J Biol Chem 2002, 277:19618-19626.
25. Hardaker E.L., Freeman M.S., Dale N., Bahra P., Raza F., Banner K.H., et al. Exposing rodents to a combination of tobacco smoke and lipopolysaccharide results in an exaggerated inflammatory response in the lung. Br J Pharmacol 2010, 160:1985-1996.
26. Zhou Y., Tan X., Kuang W., Liu L., Wan L. Erythromycin ameliorates cigarette-smoke-induced emphysema and inflammation in rats. Transl Res 2012, 159:464-472.
27. Choi W.I., Syrkina O., Kwon K.Y., Quinn D.A., Hales C.A. JNK activation is responsible for mucus overproduction in smoke inhalation injury. Respir Res 2010, 11:172.
28. Zhong C.Y., Zhou Y.M., Pinkerton K.E. NF-κB inhibition is involved in tobacco smoke-induced apoptosis in the lungs of rats. Toxicol Appl Pharmacol 2008, 230:150-158.
29. Gaschler G.J., Skrtic M., Zavitz C.C., Lindahl M., Onnervik P.O., Murphy T.F., et al. Bacteria challenge in smoke-exposed mice exacerbates inflammation and skews the inflammatory profile. Am J Respir Crit Care Med 2009, 179:666-675.
30. Schild S., Lamprecht A.K., Fourestier C., Lauriano C.M., Klose K.E., Reidl J. Characterizing lipopolysaccharide and core lipid A mutant O1 and O139 Vibrio cholerae strains for adherence properties on mucus-producing cell line HT29-Rev MTX and virulence in mice. Int J Med Microbiol 2005, 295:243-251.